In Purdue Pharma bankruptcy settlement, OxyContin's many victims may receive nothing at all

A former member of the creditors committee managing Purdue's bankruptcy speaks out about deliberations

Opinion | Opioid Crisis: Purdue Pharma/ Sackler Family Fails in End Run around Justice

The Sacklers wanted to retreat back into their money and vast profiteering.

U.S. Seeks to Block Bankruptcy Plan That Would Free Sacklers From Opioid Claims

The Justice Department has been appealing the deal, approved earlier this month.

Opinion | The Sacklers Are Walking Off Into the Sunset. Reform the System.

The Purdue Pharma bankruptcy case settlement protected the wealthy and ignored those who suffered.

Afghanistan and the Purdue Pharma Case are Reminders That the U.S. is a Failed Narco-State, Too

Official figures state that 841,000 Americans died from drug overdoses between 1999 and 2019, and that opioids caused 70.6 percent of drug overdose deaths in 2019. The CDC also reports that in 2020, overdoses spiked by about 30 percent for all...

Opinion | America Desperately Needs a Much Better F.D.A.

The agency that regulates drug safety has become too cozy with the industry it’s supposed to oversee.

'Catastrophic Injustice': Judge OKs Purdue Pharma Bankruptcy Plan Shielding Sacklers

"Allowing the billionaires at the root of the opioid crisis to walk free while thousands of its victims are in prison is a catastrophic injustice," said Rick Claypool of Public Citizen.

Origins of an Epidemic: Purdue Pharma Knew Its Opioids Were Widely Abused (Published 2018)

A confidential Justice Department report found the company was aware early on that OxyContin was being crushed and snorted for its powerful narcotic, but continued to promote it as less addictive.

Purdue Pharma Is Dissolved and Sacklers Pay $4.5 Billion to Settle Opioid Claims

The ruling in bankruptcy court caps a long legal battle over the fate of a company accused of fueling the opioid epidemic and the family that owns it.

Richard Sackler Says Family and Purdue Bear No Responsibility for Opioid Crisis

In a rare courtroom appearance, the former Purdue Pharma president and board member was evasive and defiant.

Sacklers Threaten to Pull Out of Opioid Settlement Without Broad Legal Immunity

In a rare court appearance, David Sackler said he and his family would withdraw their pledge to pay $4.5 billion, unless they are shielded from lawsuits related to Purdue Pharma.

Opinion | In the Opioid Epidemic, More Reasons for Hope Than Despair

After years of dithering and a surge in overdose deaths, we have an administration that seems able to distinguish between effective and ineffective approaches.

Purdue Pharma drove the opioid crisis. The American Medical Association still took millions from it.

The prestigious doctor's group has made it virtually impossible to discern where public health guidance ends and industry interests begin.

We Are Releasing the Full Video of Richard Sackler’s Testimony About Purdue Pharma and the Opioid Crisis

A settlement is about to shield members of the Sackler family from civil litigation regarding their alleged roles in the opioid crisis. So it’s a good time to release the full video of Richard Sackler’s 2015 deposition.

States and Cities Near Tentative $26 Billion Deal in Opioids Cases

The agreement would end thousands of lawsuits against the three largest distributors and Johnson & Johnson and require them to pay billions for addiction treatment and prevention.

15 States Reach a Deal With Purdue Pharma, Advancing a $4.5 Billion Opioids Settlement

The states, including Massachusetts and New York, agreed to drop opposition to the bankruptcy organization plan of the company, the maker of OxyContin.

Major Trial Against Opioid Suppliers Begins in New York

New York’s sweeping lawsuit is the first opioid case in which a jury rather than a judge will decide the outcome.

Judge Clears Purdue Pharma’s Restructuring Plan for Vote by Thousands of Claimants

The ruling was a milestone in yearslong efforts to make the OxyContin manufacturer pay for its role in the opioid crisis, but some plaintiffs feel the plan doesn’t go far enough.